PERIOGARD MOUTHWASH
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
03-12-2019
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
CHLORHEXIDINE GLUCONATE
Available from:
COLGATE-PALMOLIVE CANADA INC
ATC code:
A01AB03
INN (International Name):
CHLORHEXIDINE
Dosage:
0.12%
Pharmaceutical form:
MOUTHWASH
Composition:
CHLORHEXIDINE GLUCONATE 0.12%
Administration route:
BUCCAL
Units in package:
470ML
Prescription type:
Prescription
Therapeutic area:
MISCELLANEOUS ANTI-INFECTIVES
Product summary:
Active ingredient group (AIG) number: 0107629007; AHFS:
Authorization status:
CANCELLED POST MARKET
Authorization date:
2018-10-10
Summary of Product characteristics
Page 1 of 19
PRODUCT MONOGRAPH
PERIOGARD
Chlorhexidine Gluconate 0.12% Oral Rinse, USP
Liquid, 0.12% Chlorhexidine Gluconate
Antigingivital Oral Rinse
Colgate-Palmolive Canada Inc. Date of Revision:
Two Morneau Shepell Centre
December 3, 2019
5
th
Floor, 895 Don Mills Road
Toronto, Ontario M3C 1W3
Submission Control No: 232067
Page 2 of 19
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
.......................................................................................................................
4
WARNINGS AND PRECAUTIONS
.....................................................................................................
4
ADVERSE REACTIONS
.......................................................................................................................
5
DOSAGE AND ADMINISTRATION
.....................................................................................................
6
OVERDOSAGE
.....................................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
8
STORAGE AND STABILITY
................................................................................................................
9
SPECIAL HANDLING INSTRUCTIONS
............................................................................................
10
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................. 10
PART II: SCIENTIFIC INFORMATION
..................................................................................................
11
P
Read the complete document
